---
figid: PMC9652818__40164_2022_357_Fig3_HTML
figtitle: 'N6-methyladenosine (m6A) modifications in gynecologic cancers: mechanisms
  and therapeutic targeting'
organisms:
- Mus musculus
- Human papillomavirus
- Transposon gamma-delta
- Human papillomavirus type 16
- Drosophila melanogaster
- Homo sapiens
organisms_ner:
- Homo sapiens
- Mus musculus
- Drosophila melanogaster
- Danio rerio
pmcid: PMC9652818
filename: 40164_2022_357_Fig3_HTML.jpg
figlink: /pmc/articles/PMC9652818/figure/Fig3/
number: F3
caption: In EC, m6A regulatory proteins contribute to tumorigenesis and metastasis
  by interacting with various RNAs. METTL14 mutation or reduced expression of METTL3
  increases the proliferation and tumorigenicity of EC by activating the AKT pathway.
  WTAP downregulates CAV‐1 expression to activate the NF‐κB signaling pathway in EC,
  promoting EC progression. HIF-1α and HIF-2α activate the expression of ALKBH5 under
  hypoxic conditions, facilitating the SOX2 expression by demethylating the SOX2 mRNA,
  leading to the tumorigenesis of EC. ALKBH5 demethylates the target transcript IGF1R
  and enhances its mRNA stability to promote tumorigenesis and metastasis of EC. FTO
  promotes HOXB13 protein expression, activates the WNT signaling pathway, and promotes
  EC invasion and metastasis. PADI2 activates the IGF2BP1 expression and helps in
  maintaining the mRNA stability and expression of SOX2, thereby supporting the malignancy
  state of EC. IGF2BP1 recruits PABPC1 to promote PEG10 protein expression, contributing
  to the tumorigenesis of EC. YTHDF2 inhibits the expression of IRS1 and inhibits
  IRS1/AKT signaling pathway, consequently inhibiting the tumorigenicity of EC. YTHDF2-mediated
  LncRNA FENDRR degradation promotes cellular proliferation by elevating the SOX4
  expression in EC
papertitle: 'Roles of N6-methyladenosine (m6A) modifications in gynecologic cancers:
  mechanisms and therapeutic targeting.'
reftext: Jiahua Chen, et al. Exp Hematol Oncol. 2022;11:98.
year: '2022'
doi: 10.1186/s40164-022-00357-z
journal_title: Experimental Hematology & Oncology
journal_nlm_ta: Exp Hematol Oncol
publisher_name: BioMed Central
keywords: N6-methyladenosine | Gynecologic cancer | Tumor microenvironment | Prognosis
  | Treatment
automl_pathway: 0.8602561
figid_alias: PMC9652818__F3
figtype: Figure
redirect_from: /figures/PMC9652818__F3
ndex: ''
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC9652818__40164_2022_357_Fig3_HTML.html
  '@type': Dataset
  description: In EC, m6A regulatory proteins contribute to tumorigenesis and metastasis
    by interacting with various RNAs. METTL14 mutation or reduced expression of METTL3
    increases the proliferation and tumorigenicity of EC by activating the AKT pathway.
    WTAP downregulates CAV‐1 expression to activate the NF‐κB signaling pathway in
    EC, promoting EC progression. HIF-1α and HIF-2α activate the expression of ALKBH5
    under hypoxic conditions, facilitating the SOX2 expression by demethylating the
    SOX2 mRNA, leading to the tumorigenesis of EC. ALKBH5 demethylates the target
    transcript IGF1R and enhances its mRNA stability to promote tumorigenesis and
    metastasis of EC. FTO promotes HOXB13 protein expression, activates the WNT signaling
    pathway, and promotes EC invasion and metastasis. PADI2 activates the IGF2BP1
    expression and helps in maintaining the mRNA stability and expression of SOX2,
    thereby supporting the malignancy state of EC. IGF2BP1 recruits PABPC1 to promote
    PEG10 protein expression, contributing to the tumorigenesis of EC. YTHDF2 inhibits
    the expression of IRS1 and inhibits IRS1/AKT signaling pathway, consequently inhibiting
    the tumorigenicity of EC. YTHDF2-mediated LncRNA FENDRR degradation promotes cellular
    proliferation by elevating the SOX4 expression in EC
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - CAV1
  - METTL3
  - WTAP
  - MMUT
  - METTL14
  - AKT1
  - AKT2
  - AKT3
  - FTO
  - HOXB13
  - ALKBH5
  - SOX2
  - NFKB1
  - IGF1R
  - YTHDF1
  - YTHDF2
  - IGF2BP1
  - PADI2
  - PHLPP2
  - PRR5
  - MTOR
  - PRR5L
  - IRS1
  - FENDRR
  - PEG10
  - SOX4
  - Cav1
  - Mettl3
  - Wtap
  - Mmut
  - Mettl14
  - Akt1
  - Fto
  - Hoxb13
  - Alkbh5
  - Sox2
  - Nfkb1
  - Igf1r
  - Ythdf1
  - Ythdf2
  - Igf2bp1
  - B4galnt2
  - Padi2
  - Phlpp2
  - Prr5
  - Mtor
  - Prr5l
  - Irs1
  - Fendrr
  - Peg10
  - Sox4
  - CkIIbeta
  - Andorra
  - Anp
  - Acam
  - Akt
  - Dif
  - dl
  - Rel
  - Imp
  - Tor
  - cav1
  - mettl3
  - wtap
  - mmut
  - mettl14
  - fto
  - alkbh5
  - sox2
  - ythdf1
  - ythdf2
  - igf2bp1
  - padi2
  - phlpp2
  - prr5a
  - prr5b
  - mtor
  - prr5l
  - irs1
  - sox4a
  - FTO
  - PEG
---
